Retatrutide

Retatrutide exerts a potent activating effect on the GLP-1 receptor (GLP-1R) signaling pathway, and it elicits glucose-dependent insulin secretion by exerting its biological activity at both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the GLP-1R, with a dual-receptor activation mechanism that amplifies its hypoglycemic efficacy. As a novel synthetic peptide specifically developed for metabolic disorder management, Retatrutide boasts prominent glucose-lowering properties and acts as a highly effective antidiabetic agent for the treatment of type 2 diabetes (T2D); it precisely modulates islet cell function by stimulating insulin release from pancreatic β-cells and suppressing excessive glucagon secretion from α-cells in a strictly glucose-dependent manner, ensuring blood sugar regulation without triggering the risk of hypoglycemia, a key advantage in clinical application. In addition to its core hypoglycemic and anti-diabetic effects, preclinical and clinical studies have consistently demonstrated that Retatrutide can effectively delay gastric emptying to slow down nutrient absorption, significantly reduce both fasting and postprandial blood glucose concentrations to maintain glycemic stability throughout the day, and exert a robust anorexigenic effect to decrease voluntary food intake in patients with type 2 diabetes; these synergistic actions further translate into significant body weight reduction, making it a promising therapeutic option that addresses both hyperglycemia and overweight/obesity, two major clinical challenges in the management of type 2 diabetes.